Skip Navigation LinksHome > July 2013 - Volume 38 - Issue 7 > 18F-Fluorothymidine PET Is a Potential Predictive Imaging Bi...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318292ee9c
Interesting Images

18F-Fluorothymidine PET Is a Potential Predictive Imaging Biomarker of the Response to Gemcitabine-Based Chemotherapeutic Treatment for Recurrent Ovarian Cancer: Preliminary Results in Three Patients

Tsuyoshi, Hideaki MD*; Morishita, Fumiko MD*; Orisaka, Makoto MD*; Okazawa, Hidehiko MD; Yoshida, Yoshio MD*

Collapse Box

Abstract

Abstract: In order to establish early and precise methods for evaluating the effect of secondary chemotherapy in patients with recurrent ovarian cancer, both the clinical course of 3 women treated with gemcitabine-based secondary chemotherapy and the potential for early and accurate evaluation of the secondary chemotherapeutic effect of 18F-fluorothymidine (FLT) PET are reported. Standard uptake value with FLT PET decreased earlier than with 18F-fluorodeoxyglucose PET and was better correlated with a reduction in size as measured by CT. FLT PET could become a new standard for monitoring response to gemcitabine-based secondary chemotherapy treatment for recurrent ovarian cancer.

© 2013 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.